← Back to screener

Inhibikase Therapeutics, Inc. IKT

Rank #2417 · Nasdaq · $0.2B market cap
Audited by CohnReznick LLP, no going-concern flag in the latest filing.
Score
19.7
P/E
-7.4
P/B
18.64
ROE
-250.7%
Op. Margin
–%
Debt Ratio
34%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -7.4x, P/B 18.64x. Ranks in the top 87% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -250.7%. Ranks in the top 98% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 34%. Ranks in the top 18% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.0B$-0.0B$-0.0B-403.5-111
2022$0.0B$-0.0B$-0.0B$0.0B-476.241
2023$0.0B$-0.0B$-0.0B$0.0B-14686.210
2024$0.0B$-0.0B$-0.0B$0.0B-7712.017
2025–$-0.0B$-0.0B$0.0B–34

← See the full screener